

NIH funding opportunities

14 January 2025 (#01)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

NOT-HS-25-006 New "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025. The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form
- PHS Assignment Request Form
- PHS 398 Cover Page Supplement Form

Application guides for FORMS-I application packages will be posted to the [How to Apply - Application Guide](#) page in November 2024.

NOT-AI-25-007 Request for Information (RFI): Researching COVID to Enhance Recovery – Treating Long COVID (RECOVER-TLC). Today, there are no approved therapies to treat Long COVID or its symptoms, leaving millions of patients suffering and waiting for answers. Trying to counter this public health crisis, the NIH announced the next phase of its Long COVID research program: Researching COVID to Enhance Recovery–Treating Long COVID (RECOVER-TLC) led by National Institute of Allergy and Infectious Disease (NIAID), in collaboration with National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS). The goal of this initiative is to work rapidly, collaboratively, and transparently to advance treatments for Long COVID. RECOVER-TLC will apply lessons learned from the ongoing program, RECOVER, launched in 2021. Responses may be submitted up until 12:00 AM EST February 1, 2025. Please direct all inquiries to: recover-tlc-submissions@nih.gov

NOT-HG-25-011 Notice of Intent to Publish a Funding Opportunity Announcement for Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional). The purpose of this Notice is to inform the research community that the National Human Genome Research Institute (NHGRI) intends to publish a renewal of RFA-HG-22-001: Supporting Talented Early Career Researchers in Genomics. This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. Expected Number of Awards: 3-5 per year. Estimated Award

Ceiling: Application budgets are limited to less than \$400,000 in direct costs per year and must reflect the actual needs of the proposed project. First Estimated Application Due Date: February 28, 2025.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-25-301](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-25-303](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-25-305](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-25-302](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-25-304](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-25-306](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-25-307](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-CA-25-003](#) **Implementation Science for Climate Change and Health.** The purpose of this Notice is to inform potential applicants of the interest of the NIH Climate Change and Health Initiative (CCHI) in supporting implementation science related to climate change and health. The CCHI seeks to reduce the health threats posed by climate change across the lifespan, improve the health of people who are at increased risk from or disproportionately impacted by climate change, and build health resilience among individuals, organizations, communities, Tribal Nations, and nations around the world. This NOSI encourages applications that propose implementation studies to understand and address barriers and facilitators to the adoption, implementation, scale-up, and sustainment of effective interventions to prevent or mitigate the health effects of climate change in the United States and globally. This Notice applies to application due dates on or after February 5, 2025 through to through January 7, 2028

[NOT-CA-25-012](#) **Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments.** The purpose of this notice of special interest (NOSI) is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs). This Notice applies to application due dates on or after October 5, 2024, and subsequent receipt dates through January 7, 2028.

Notice of Funding Opportunity (NOFO)

[RFA-AI-24-023](#) **U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional).** The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science. The hallmark of the U.S.-South Africa program is the development of collaborative partnerships between South African investigators and United States (U.S.) investigators. Through international collaboration, this research will advance scientific discoveries, promote sharing of technologies and approaches, and serve local public health needs and priorities in support of global HIV/AIDS research.

AIDS Date: March 12, 2025. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent:** 30 days prior to the application due date.

Budget: Issuing IC and partner components intend to commit an estimated total of \$3.8 million to fund 8-10 awards. Application budgets are not expected to exceed \$400,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Important Notice: All potential applicants **MUST** inform the Grants Management Office **before** 12 January 2025 of their intention to apply. This must include the specific aims, participating institutions and list of all key personnel and consultants. Only after receiving this internal letter of intent, meetings with the PI will be scheduled and project plans will be prepared. **Please also contact the Scientific Program officials** listed in the NOFO to ensure that your application is responsive to the call.

PAR-25-063 Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed). The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

Date: February 05, 2025 through to May 07, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

PAR-25-082 Co-infection and Cancer (R01 Clinical Trial Not Allowed). The purpose of this Notice of Funding Opportunity (NOFO) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

Date: June 05, 2025; October 05, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

PA-25-253 Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). The overall goals of this NOFO are to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies.

Date: June 16, 2025 through to June 16, 2028. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

PAR-24-306 Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed). The NCI, through this NOFO, encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Date: June 05, 2025 through to June 05, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$499,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-24-325 Bioengineering Partnerships with Industry \(U01 Clinical Trial Optional\)](#). This NOFO solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfil an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years.

Date: May 28, 2025 through to September 07, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-036 Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders \(R01 Clinical Trial Optional\)](#). This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIA

Date: June 05, 2025 through to May 07, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but, need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years.

[PAR-25-049 NIH SIREN Neurologic Clinical Trials \(UG3/UH3 - Clinical Trial Required\)](#). This Notice of Funding Opportunity (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this NOFO. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.

Date: June 06, 2025 through to February 06, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The typical project period is 5 years. The UG3 phase is a maximum of 2 years and UH3 phase a maximum of 5 years. Should a project require more than five years of support, special permission should be requested from NINDS prior to submission of the grant.

[PAR-25-063 Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders \(R01 Clinical Trial Not Allowed\)](#). The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

Date: June 05, 2025 through to May 07, 2026 All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-079 Academic-Industrial Partnerships \(AIP\) to Translate and Validate In Vivo Imaging Systems \(R01 Clinical Trial Optional\)](#). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

Date: October 05, 2025 through to October 05, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budget is limited to less than \$500,000 direct cost per year and must reflect the actual needs of the proposed project. The maximum project period is 5 years.

[PAR-25-082 Co-infection and Cancer \(R01 Clinical Trial Not Allowed\)](#). The purpose of this Notice of Funding Opportunity (NOFO) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

Date: June 05, 2025 and October 05, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

[PAR-25-083 Co-infection and Cancer \(R21 Clinical Trial Not Allowed\)](#). The overall goals of this NOFO are to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies.

Date: June 16, 2025 & October 16, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

[PAR-25-103 Cancer Prevention and Control Clinical Trials Planning Grant Program \(U34 Clinical Trials Optional\)](#). Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviours, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

Date: June 25, 2025 through to October 25, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$225,000 per year and \$450,000 in direct costs over the 3-year project period without a clinical trial. Applications that include a pilot/ feasibility clinical trial are limited to \$225,000 per year and \$600,000 in direct costs over the 3-year project period. The maximum project period is three years.

PAR-25-104 Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional).

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviours, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

Date: June 25, 2025 through to October 25, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$225,000 per year and \$450,000 in direct costs over the 3-year project period without a clinical trial. Applications that include a pilot/feasibility clinical trial are limited to \$225,000 per year and \$600,000 in direct costs over the 3-year project period. The maximum project period is three years.

PAR-25-107 Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed).

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumours, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumour agents, as activators of anti-tumour immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumour aspects of microbial tumour interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumour imaging, tumour detection, or diagnosis.

Date: February 05, 2025 All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

PAR-25-108 Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed).

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumours, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumour agents, as activators of anti-tumour immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumour aspects of microbial tumour interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumour imaging, tumour detection, or diagnosis

Date: February 16, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

PAR-25-136 Laboratories to Optimize Digital Health (R01 Clinical Trial Required).

NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviours and serious mental illness. This Notice of Funding Opportunity (NOFO) is intended to support the development of digital health test beds that leverage well-established digital health platforms and infrastructure to rapidly refine and optimize

existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.

Date: June 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 4 years.

[PAR-25-139](#) NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This NOFO does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioural interventions. These applications will be deemed not responsive to this NOFO and will not be reviewed (see below for a more detailed description of studies that are not responsive for this NOFO). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

Date: June 12, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

[PAR-25-140](#) In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed). The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

Date: June 05, 2025 & October 05, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Budgets with direct costs of up to \$499,999 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-145](#) Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional). The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research

projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Date: June 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-146](#) Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed). The purpose of this notice of funding opportunity (NOFO) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.

Date: June 05, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are limited to \$499,999 Direct Costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-153](#) Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed). Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

Date: June 05, 2025 through to June 05, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 3 years.

[PAR-25-186](#) Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed). Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement. The goal of this NOFO is to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies.

Date: February 28, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-198](#) Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed). This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in

healthy and disease states. This NOFO is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 NOFO [PAR-25-199](#).

Date: June 05, 2025 & October 05, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-201](#) Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional). This notice of funding opportunity (NOFO) seeks implementation research projects focused on the integrating mental health services with chronic health care (for both communicable and non-communicable conditions) across various healthcare and non-healthcare settings (such as schools, places of worship, and community centers) in low and middle-income countries (LMICs). The objective is to develop, refine, and evaluate innovative strategies to facilitate the integration of mental health care with other services. This NOFO aims to support research geared towards implementing, scaling up, and ensuring the financial sustainability of integrated mental health care models, with the overarching goal of enhancing the availability, accessibility, utilization, and quality of mental health care services in both healthcare and non-healthcare settings. In addition, this NOFO seeks to strengthen sustainable mental health research capacity in LMICs.

Date: June 05, 2025 through to October 05, 2027. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-25-221](#) Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional). This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations. The overall goals of this NOFO are to: 1) provide fundamental information on the cause and nature of cancer in people, with the expectation that this will result in better methods of prevention, detection and diagnosis, and treatment of neoplastic diseases; 2) develop a sound fundamental knowledge base which can be applied to the development of improved methods of treatment and more effective strategies for preventing alcoholism and alcohol-related problems.

Date: June 05, 2025 through to October 05, 2026. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add “Interest in NIH opportunity” in the subject line.

Add the notice number with hyperlink in the text of the email.